{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:42:00Z","timestamp":1792773720386,"version":"4.5.0"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. Recent discoveries identifying circulating antiangiogenic factors\u2014particularly soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin\u2014as key mediators of the maternal syndrome have transformed understanding of its pathogenesis. These insights have led to the development of molecular diagnostics, such as sFlt-1, placental growth factor, and their ratio, now integrated into clinical practice for improved prediction, diagnosis, and management. The serum sFlt-1\/placental growth factor is particularly useful for nephrologists for early detection of superimposed preeclampsia in pregnant women with CKD. Emerging therapeutic strategies\u2014including targeted apheresis, recombinant ligands, RNA-based interventions, and small-molecule modulators\u2014offer promise for disease modification. Preeclampsia also confers long-term cardiovascular and kidney risks for mothers and adverse pulmonary outcomes for offspring, underscoring its lifelong effect. Progress in preeclampsia care will depend on sustained scientific innovation and the responsible inclusion of pregnant women in clinical trials to ensure that future diagnostics and therapies are both safe and effective for both mother and baby.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000001197","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:00:27Z","timestamp":1783526427000},"page":"2030-2041","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Transforming Preeclampsia Care"],"prefix":"10.1681","volume":"37","author":[{"given":"Ravi","family":"Thadhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-6831","authenticated-orcid":false,"given":"Subbian Ananth","family":"Karumanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"10297","key":"B1-20261023","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"Chappell","year":"2021","journal-title":"Lancet."},{"key":"B2-20261023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejogrb.2020.03.043","article-title":"Prevalence of preeclampsia and eclampsia in adolescent pregnancy: a systematic review and meta-analysis of 291,247 adolescents worldwide since 1969","volume":"248","author":"Macedo","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"3","key":"B3-20261023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","article-title":"Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol."},{"issue":"8","key":"B4-20261023","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"B5-20261023","doi-asserted-by":"crossref","first-page":"e23441","DOI":"10.1096\/fj.202301808R","article-title":"Translation of mechanistic advances in preeclampsia to the clinic: long and winding road","volume":"38","author":"Thadhani","year":"2024","journal-title":"FASEB J."},{"issue":"7","key":"B6-20261023","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"Rana","year":"2019","journal-title":"Circ Res."},{"issue":"2S","key":"B7-20261023","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.ajog.2021.11.1356","article-title":"The etiology of preeclampsia","volume":"226","author":"Jung","year":"2022","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"B8-20261023","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/HYPERTENSIONAHA.113.01505","article-title":"Preeclampsia is associated with the presence of transcriptionally active placental fragments in the maternal lung","volume":"62","author":"Buurma","year":"2013","journal-title":"Hypertension."},{"key":"B9-20261023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.preghy.2017.07.142","article-title":"Labor therapeutics and BMI as risk factors for postpartum preeclampsia: a case-control study","volume":"10","author":"Skurnik","year":"2017","journal-title":"Pregnancy Hypertens."},{"issue":"5","key":"B10-20261023","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0002-9378(89)90665-0","article-title":"Preeclampsia: an endothelial cell disorder","volume":"161","author":"Roberts","year":"1989","journal-title":"Am J Obstet Gynecol."},{"issue":"2S","key":"B11-20261023","doi-asserted-by":"crossref","first-page":"S1035","DOI":"10.1016\/j.ajog.2021.11.1350","article-title":"Discovery of antiangiogenic factors in the pathogenesis of preeclampsia","volume":"226","author":"Karumanchi","year":"2022","journal-title":"Am J Obstet Gynecol."},{"issue":"5","key":"B12-20261023","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest."},{"issue":"8","key":"B13-20261023","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1681\/ASN.2007020255","article-title":"The glomerular injury of preeclampsia","volume":"18","author":"Stillman","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B14-20261023","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"New Engl J Med."},{"issue":"5","key":"B15-20261023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1161\/CIRCULATIONAHA.109.895458","article-title":"Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension","volume":"122","author":"Noori","year":"2010","journal-title":"Circulation."},{"issue":"6","key":"B16-20261023","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nm1429","article-title":"Soluble endoglin contributes to the pathogenesis of preeclampsia","volume":"12","author":"Venkatesha","year":"2006","journal-title":"Nat Med."},{"issue":"10","key":"B17-20261023","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med."},{"issue":"1","key":"B18-20261023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","article-title":"A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate","volume":"21","author":"Romero","year":"2008","journal-title":"J Matern Fetal Neonatal Med."},{"issue":"2","key":"B19-20261023","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","article-title":"Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR","volume":"226","author":"Kendall","year":"1996","journal-title":"Biochem Biophys Res Commun."},{"issue":"22","key":"B20-20261023","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"B21-20261023","doi-asserted-by":"crossref","first-page":"12139","DOI":"10.1038\/s41598-017-11639-6","article-title":"FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia","volume":"7","author":"Ashar-Patel","year":"2017","journal-title":"Sci Rep."},{"issue":"14","key":"B22-20261023","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1096\/fj.07-8809com","article-title":"Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta","volume":"21","author":"Thomas","year":"2007","journal-title":"FASEB J."},{"issue":"3","key":"B23-20261023","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.placenta.2008.12.010","article-title":"Novel splice variants of sFlt1 are upregulated in preeclampsia","volume":"30","author":"Heydarian","year":"2009","journal-title":"Placenta."},{"issue":"12","key":"B24-20261023","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1161\/CIRCRESAHA.108.171504","article-title":"A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia","volume":"102","author":"Sela","year":"2008","journal-title":"Circ Res."},{"key":"B25-20261023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.preghy.2019.03.013","article-title":"Circulating soluble fms-like tyrosine kinase-1 is placentally derived in normal pregnancy: first in vivo evidence","volume":"16","author":"Cerdeira","year":"2019","journal-title":"Pregnancy Hypertens."},{"issue":"3","key":"B26-20261023","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.120.15338","article-title":"Total versus free placental growth factor levels in the pathogenesis of preeclampsia","volume":"76","author":"Lecarpentier","year":"2020","journal-title":"Hypertension."},{"issue":"5","key":"B27-20261023","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/HYPERTENSIONAHA.125.24736","article-title":"Total and free placental growth factor levels during preeclampsia and fetal growth restriction","volume":"82","author":"Jungelson","year":"2025","journal-title":"Hypertension."},{"issue":"2","key":"B28-20261023","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"5","key":"B29-20261023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest."},{"issue":"12","key":"B30-20261023","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for Anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer."},{"issue":"1","key":"B31-20261023","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00441-003-0776-3","article-title":"VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis","volume":"314","author":"Tjwa","year":"2003","journal-title":"Cell Tissue Res."},{"issue":"7","key":"B32-20261023","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1172\/JCI83918","article-title":"Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia","volume":"126","author":"Burke","year":"2016","journal-title":"J Clin Invest."},{"issue":"6B","key":"B33-20261023","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00820.x","article-title":"Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model","volume":"14","author":"Bergmann","year":"2010","journal-title":"J Cell Mol Med."},{"issue":"4","key":"B34-20261023","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/HYPERTENSIONAHA.107.092098","article-title":"Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia","volume":"50","author":"Li","year":"2007","journal-title":"Hypertension."},{"issue":"11","key":"B35-20261023","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1172\/JCI99026","article-title":"Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice","volume":"128","author":"Parchem","year":"2018","journal-title":"J Clin Invest."},{"issue":"7","key":"B36-20261023","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.4049\/jimmunol.178.7.4267","article-title":"Genetic deletion of placenta growth factor in mice alters uterine NK cells","volume":"178","author":"Tayade","year":"2007","journal-title":"J Immunol."},{"issue":"3","key":"B37-20261023","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension."},{"issue":"4","key":"B38-20261023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"B39-20261023","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med."},{"issue":"2","key":"B40-20261023","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B41-20261023","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ng.3895","article-title":"Variants in the fetal genome near FLT1 are associated with risk of preeclampsia","volume":"49","author":"McGinnis","year":"2017","journal-title":"Nat Genet."},{"issue":"5","key":"B42-20261023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.124.23400","article-title":"Genetic variants associated with preeclampsia and maternal serum sFLT1 levels","volume":"82","author":"Mack","year":"2025","journal-title":"Hypertension."},{"issue":"4S","key":"B43-20261023","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajog.2025.01.041","article-title":"Placenta at single-cell resolution in early and late preeclampsia: insights and clinical implications","volume":"232","author":"Solt","year":"2025","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"B44-20261023","doi-asserted-by":"crossref","first-page":"bqac012","DOI":"10.1210\/endocr\/bqac012","article-title":"Placental sFlt-1 gene delivery in early primate pregnancy suppresses uterine spiral artery remodeling","volume":"163","author":"Aberdeen","year":"2022","journal-title":"Endocrinology."},{"issue":"4","key":"B45-20261023","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/HYPERTENSIONAHA.121.17567","article-title":"Circulating maternal sFLT1 (soluble fms-like tyrosine kinase-1) is sufficient to impair spiral arterial remodeling in a preeclampsia mouse model","volume":"78","author":"Vogtmann","year":"2021","journal-title":"Hypertension."},{"issue":"2","key":"B46-20261023","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/HYPERTENSIONAHA.111.182170","article-title":"Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"59","author":"Rajakumar","year":"2012","journal-title":"Hypertension."},{"issue":"2S","key":"B47-20261023","doi-asserted-by":"crossref","first-page":"S907","DOI":"10.1016\/j.ajog.2020.09.047","article-title":"Syncytiotrophoblast stress in preeclampsia: the convergence point for multiple pathways","volume":"226","author":"Redman","year":"2022","journal-title":"Am J Obstet Gynecol."},{"issue":"36","key":"B48-20261023","doi-asserted-by":"crossref","first-page":"17800","DOI":"10.1073\/pnas.1816661116","article-title":"Role of soluble endoglin in BMP9 signaling","volume":"116","author":"Lawera","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"24","key":"B49-20261023","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/CIRCULATIONAHA.109.853127","article-title":"Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease","volume":"123","author":"Powe","year":"2011","journal-title":"Circulation."},{"issue":"7","key":"B50-20261023","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation."},{"key":"B51-20261023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.preghy.2018.05.008","article-title":"Angiogenic biomarkers in triage and risk for preeclampsia with severe features","volume":"13","author":"Rana","year":"2018","journal-title":"Pregnancy Hypertens."},{"issue":"3","key":"B52-20261023","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10641955.2016.1148162","article-title":"KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes","volume":"35","author":"Salahuddin","year":"2016","journal-title":"Hypertens Pregnancy."},{"issue":"2","key":"B53-20261023","doi-asserted-by":"crossref","first-page":"161.e1","DOI":"10.1016\/j.ajog.2009.09.016","article-title":"An automated method for the determination of the sFlt-1\/PIGF ratio in the assessment of preeclampsia","volume":"202","author":"Verlohren","year":"2010","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"B54-20261023","doi-asserted-by":"crossref","first-page":"58.e1","DOI":"10.1016\/j.ajog.2011.07.037","article-title":"The sFlt-1\/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients","volume":"206","author":"Verlohren","year":"2012","journal-title":"Am J Obstet Gynecol."},{"key":"B55-20261023","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sFlt-1\/PlGF ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","author":"Verlohren","year":"2022","journal-title":"Pregnancy Hypertens."},{"issue":"9","key":"B56-20261023","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.clinbiochem.2010.02.010","article-title":"Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia","volume":"43","author":"Schiettecatte","year":"2010","journal-title":"Clin Biochem."},{"issue":"1","key":"B57-20261023","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.ajog.2009.07.025","article-title":"Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study","volume":"202","author":"Sunderji","year":"2010","journal-title":"Am J Obstet Gynecol."},{"issue":"5","key":"B58-20261023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2010.15","article-title":"Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia","volume":"33","author":"Ohkuchi","year":"2010","journal-title":"Hypertens Res."},{"issue":"2","key":"B59-20261023","doi-asserted-by":"crossref","first-page":"152.e1","DOI":"10.1016\/j.ajog.2010.08.049","article-title":"Circulating angiogenic and antiangiogenic factors in women with eclampsia","volume":"204","author":"Vaisbuch","year":"2011","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"B60-20261023","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/HYPERTENSIONAHA.112.201459","article-title":"Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1\/placental growth factor ratio","volume":"60","author":"Verdonk","year":"2012","journal-title":"Hypertension."},{"issue":"1","key":"B61-20261023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ki.2012.348","article-title":"Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers","volume":"83","author":"Rolfo","year":"2013","journal-title":"Kidney Int."},{"issue":"5","key":"B62-20261023","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/HYPERTENSIONAHA.108.127977","article-title":"First-trimester prediction of hypertensive disorders in pregnancy","volume":"53","author":"Poon","year":"2009","journal-title":"Hypertension."},{"issue":"2","key":"B63-20261023","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1210\/jc.2003-031244","article-title":"First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia","volume":"89","author":"Thadhani","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"B64-20261023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.111.181735","article-title":"Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy","volume":"59","author":"Perni","year":"2012","journal-title":"Hypertension."},{"key":"B65-20261023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens."},{"issue":"1","key":"B66-20261023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"New Engl J Med."},{"issue":"1","key":"B67-20261023","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension."},{"issue":"19","key":"B68-20261023","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation."},{"issue":"7","key":"B69-20261023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med."},{"key":"B70-20261023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejogrb.2016.02.013","article-title":"The sFlt-1\/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort","volume":"199","author":"Saleh","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"3","key":"B71-20261023","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/AOG.0000000000003694","article-title":"Placental growth factor and the risk of adverse neonatal and maternal outcomes","volume":"135","author":"Parchem","year":"2020","journal-title":"Obstet Gynecol."},{"issue":"5","key":"B72-20261023","doi-asserted-by":"crossref","first-page":"e0126815","DOI":"10.1371\/journal.pone.0126815","article-title":"Circulating angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia","volume":"10","author":"March","year":"2015","journal-title":"PLoS One."},{"issue":"12","key":"B73-20261023","doi-asserted-by":"crossref","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid."},{"issue":"3","key":"B74-20261023","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajog.2025.11.006","article-title":"Serum soluble fms-like tyrosine kinase kinase 1-to-placental growth factor ratio on Elecsys immunoassay platform predicts preeclampsia with severe features in hospitalized women with hypertensive disorders of pregnancy","volume":"234","author":"Berg","year":"2026","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"B75-20261023","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/AOG.0000000000005532","article-title":"Angiogenic biomarkers in preeclampsia","volume":"143","author":"Burwick","year":"2024","journal-title":"Obstet Gynecol."},{"issue":"10523","key":"B76-20261023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(25)01207-3","article-title":"Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial","volume":"407","author":"Goadsby","year":"2026","journal-title":"Lancet."},{"issue":"10183","key":"B77-20261023","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","article-title":"Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial","volume":"393","author":"Duhig","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"B78-20261023","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension."},{"issue":"4","key":"B79-20261023","doi-asserted-by":"crossref","first-page":"385.e1","DOI":"10.1016\/j.ajog.2024.07.015","article-title":"Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1\/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy","volume":"232","author":"Burns","year":"2025","journal-title":"Am J Obstet Gynecol."},{"issue":"2S","key":"B80-20261023","doi-asserted-by":"crossref","first-page":"S1037","DOI":"10.1016\/j.ajog.2020.10.028","article-title":"Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction","volume":"226","author":"Dathan-Stumpf","year":"2022","journal-title":"Am J Obstet Gynecol."},{"issue":"2","key":"B81-20261023","doi-asserted-by":"crossref","first-page":"e0263443","DOI":"10.1371\/journal.pone.0263443","article-title":"sFlt-1\/PlGF ratio for prediction of preeclampsia in clinical routine: a pragmatic real-world analysis of healthcare resource utilisation","volume":"17","author":"Dathan-Stumpf","year":"2022","journal-title":"PLoS One."},{"issue":"7","key":"B82-20261023","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41440-021-00624-2","article-title":"Economic evaluation of the sFlt-1\/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study","volume":"44","author":"Ohkuchi","year":"2021","journal-title":"Hypertens Res."},{"issue":"6","key":"B83-20261023","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/uog.15997","article-title":"sFlt-1\/PlGF ratio test for pre-eclampsia: an economic assessment for the UK","volume":"48","author":"Vatish","year":"2016","journal-title":"Ultrasound Obstet Gynecol."},{"key":"B84-20261023","doi-asserted-by":"crossref","first-page":"127083","DOI":"10.1155\/2015\/127083","article-title":"Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study","volume":"2015","author":"Rolfo","year":"2015","journal-title":"Dis Markers."},{"issue":"11","key":"B85-20261023","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/HYPERTENSIONAHA.124.23411","article-title":"Predictive and diagnostic value of the angiogenic proteins in patients with chronic kidney disease","volume":"81","author":"Melamed","year":"2024","journal-title":"Hypertension."},{"issue":"5","key":"B86-20261023","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.ekir.2021.02.029","article-title":"Clinical use of angiogenic factors in managing a pregnant woman on hemodialysis to term","volume":"6","author":"Shanmugalingam","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B87-20261023","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.ajog.2015.09.066","article-title":"Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study","volume":"214","author":"Kim","year":"2016","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"B88-20261023","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1161\/HYPERTENSIONAHA.119.13763","article-title":"Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome","volume":"75","author":"Stepan","year":"2020","journal-title":"Hypertension."},{"issue":"5","key":"B89-20261023","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.kint.2023.12.021","article-title":"A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy","volume":"105","author":"Che","year":"2024","journal-title":"Kidney Int."},{"issue":"10","key":"B90-20261023","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.125.24526","article-title":"Point-of-care placental growth factor for predicting adverse outcomes in Sierra Leone","volume":"82","author":"Kuhrt","year":"2025","journal-title":"Hypertension."},{"key":"B91-20261023","doi-asserted-by":"crossref","first-page":"101455","DOI":"10.1016\/j.preghy.2026.101455","article-title":"Prediction of severe maternal and perinatal complications in hypertensive pregnancies using point-of-care glycosylated fibronectin: a prospective cohort study","volume":"44","author":"Martin","year":"2026","journal-title":"Pregnancy Hypertens."},{"issue":"3","key":"B92-20261023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jca.2920090302","article-title":"Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome","volume":"9","author":"Martin","year":"1994","journal-title":"J Clin Apher."},{"issue":"9","key":"B93-20261023","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/0026-0495(94)90061-2","article-title":"Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis","volume":"43","author":"Kroon","year":"1994","journal-title":"Metabolism."},{"issue":"8","key":"B94-20261023","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadhani","year":"2011","journal-title":"Circulation."},{"issue":"3","key":"B95-20261023","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B96-20261023","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/s41591-026-04333-6","article-title":"Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial","volume":"32","author":"Thadhani","year":"2026","journal-title":"Nat Med."},{"key":"B97-20261023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejogrb.2018.09.009","article-title":"LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: report of two cases from a discontinued phase II trial","volume":"231","author":"Haddad","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"4","key":"B98-20261023","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/HYPERTENSIONAHA.120.14974","article-title":"Affinity-enhanced multimeric VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) variants for specific adsorption of sFlt-1 to restore angiogenic balance in preeclampsia","volume":"76","author":"Matin","year":"2020","journal-title":"Hypertension."},{"issue":"4","key":"B99-20261023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","article-title":"Placental growth factor administration abolishes placental ischemia-induced hypertension","volume":"67","author":"Spradley","year":"2016","journal-title":"Hypertension."},{"issue":"6","key":"B100-20261023","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","article-title":"Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates","volume":"67","author":"Makris","year":"2016","journal-title":"Hypertension."},{"issue":"2","key":"B101-20261023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/10641955.2022.2048390","article-title":"Cardiovascular and hemodynamic consequences of recombinant placental growth factor administration in Guinea pigs","volume":"41","author":"Y Tan","year":"2022","journal-title":"Hypertens Pregnancy."},{"key":"B102-20261023","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","volume":"36","author":"Turanov","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B103-20261023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","article-title":"Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1","volume":"29","author":"Davis","year":"2022","journal-title":"Mol Ther Nucleic Acids."},{"issue":"8045","key":"B104-20261023","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41586-024-08291-2","article-title":"Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia","volume":"637","author":"Swingle","year":"2025","journal-title":"Nature."},{"key":"B105-20261023","doi-asserted-by":"crossref","first-page":"n2103","DOI":"10.1136\/bmj.n2103","article-title":"Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial","volume":"374","author":"Cluver","year":"2021","journal-title":"BMJ."},{"issue":"3","key":"B106-20261023","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.12.019","article-title":"Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction","volume":"214","author":"Brownfoot","year":"2016","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"B107-20261023","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1073\/pnas.1011293108","article-title":"Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model","volume":"108","author":"Kumasawa","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"B108-20261023","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia","volume":"144","author":"Dobert","year":"2021","journal-title":"Circulation."},{"issue":"4","key":"B109-20261023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial","volume":"127","author":"Ahmed","year":"2020","journal-title":"BJOG."},{"issue":"3","key":"B110-20261023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","article-title":"Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction","volume":"69","author":"Onda","year":"2017","journal-title":"Hypertension."},{"issue":"4","key":"B111-20261023","doi-asserted-by":"crossref","first-page":"388.e1","DOI":"10.1016\/j.ajog.2018.07.019","article-title":"Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial","volume":"219","author":"Cluver","year":"2018","journal-title":"Am J Obstet Gynecol."},{"key":"B112-20261023","doi-asserted-by":"crossref","first-page":"103779","DOI":"10.1016\/j.eclinm.2026.103779","article-title":"Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial","volume":"92","author":"Kadife","year":"2026","journal-title":"eClinicalMedicine"},{"key":"B113-20261023","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","article-title":"Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction","volume":"41","author":"Brownfoot","year":"2019","journal-title":"eBioMedicine"},{"issue":"10","key":"B114-20261023","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1096\/fj.14-252684","article-title":"Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1alpha pathway","volume":"28","author":"Rana","year":"2014","journal-title":"FASEB J."},{"issue":"8","key":"B115-20261023","doi-asserted-by":"crossref","first-page":"e23078","DOI":"10.1096\/fj.202300611R","article-title":"Bioflavonoid luteolin prevents sFlt-1 release via HIF-1alpha inhibition in cultured human placenta","volume":"37","author":"Eddy","year":"2023","journal-title":"FASEB J."},{"issue":"47","key":"B116-20261023","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.1614947113","article-title":"Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"B117-20261023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cvr\/cvu018","article-title":"Pre-eclampsia and cardiovascular disease","volume":"101","author":"Chen","year":"2014","journal-title":"Cardiovasc Res."},{"issue":"7398","key":"B118-20261023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11040","article-title":"Cardiac angiogenic imbalance leads to peripartum cardiomyopathy","volume":"485","author":"Patten","year":"2012","journal-title":"Nature."},{"issue":"13","key":"B119-20261023","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/1471-0528.15394","article-title":"Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis","volume":"125","author":"Brouwers","year":"2018","journal-title":"BJOG."},{"issue":"1","key":"B120-20261023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/uog.15981","article-title":"Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia","volume":"50","author":"Akhter","year":"2017","journal-title":"Ultrasound Obstet Gynecol."},{"issue":"6","key":"B121-20261023","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/HYPERTENSIONAHA.124.22905","article-title":"Coronary microvascular function following severe preeclampsia","volume":"81","author":"Honigberg","year":"2024","journal-title":"Hypertension."},{"issue":"12","key":"B122-20261023","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1210\/jc.2004-0548","article-title":"Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance","volume":"89","author":"Wolf","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"B123-20261023","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1161\/CIRCRESAHA.122.321228","article-title":"Smooth muscle mineralocorticoid receptor promotes hypertension after preeclampsia","volume":"132","author":"Biwer","year":"2023","journal-title":"Circ Res."},{"issue":"4","key":"B124-20261023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/HYPERTENSIONAHA.114.04971","article-title":"Exposure to experimental preeclampsia in mice enhances the vascular response to future injury","volume":"65","author":"Pruthi","year":"2015","journal-title":"Hypertension."},{"issue":"4","key":"B125-20261023","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ndt\/gfaf226","article-title":"Diagnosis, diagnostic approach and challenges in pregnancy-associated AKI-the ADQI 32 consensus meeting","volume":"41","author":"Lumlertgul","year":"2026","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B126-20261023","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0706790","article-title":"Preeclampsia and the risk of end-stage renal disease","volume":"359","author":"Vikse","year":"2008","journal-title":"N Engl J Med."},{"issue":"11","key":"B127-20261023","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2215\/CJN.01820212","article-title":"Familial factors in the association between preeclampsia and later ESRD","volume":"7","author":"Vikse","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B128-20261023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jpeds.2009.10.018","article-title":"Maternal preeclampsia predicts the development of bronchopulmonary dysplasia","volume":"156","author":"Hansen","year":"2010","journal-title":"J Pediatr."},{"issue":"1","key":"B129-20261023","doi-asserted-by":"crossref","first-page":"L36","DOI":"10.1152\/ajplung.00294.2011","article-title":"Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia","volume":"302","author":"Tang","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"issue":"6","key":"B130-20261023","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","article-title":"Preeclampsia: a renal perspective","volume":"67","author":"Karumanchi","year":"2005","journal-title":"Kidney Int."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:01:15Z","timestamp":1792771275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001197"}},"subtitle":["Molecular Diagnostics and Therapeutic Innovations"],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":130,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001197","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}